LAMB3 Full Name
laminin, beta 3
LAMB3 Introduction
Laminin subunit beta-3 (LAMB3) encodes the beta 3 chain of the extracellular matrix protein laminin-332 (formerly known as laminin-5), which is a heterotrimer composed of alpha, beta, and gamma chains. Laminins are major components of basement membranes and play crucial roles in mediating cell adhesion, migration, differentiation, and organization of tissues during embryonic development and in maintenance of adult tissue integrity. The LAMB3-encoded beta 3 subunit specifically contributes to the structural and functional properties of laminin-332, supporting the attachment of epithelial cells to underlying connective tissue and participating in processes such as wound healing, corneal integrity, and enamel formation of teeth. This adhesive function is achieved through interactions with high-affinity cell surface receptors and other extracellular matrix molecules, and aberrations in laminin networks can compromise tissue architecture and cell signaling.
Figure 1. The proposed mechanism of LAMB3-mediated tumor antiapoptotic signaling, invasion and metastasis through the PI3K/Akt axis in patients with pancreatic ductal adenocarcinoma (PDAC).(Sources: Zhang H, et al.; 2019)
Functionally, LAMB3 is involved not only in basic structural roles but also in dynamic cellular behaviors. In normal physiology, laminin-332 influences cell motility and survival, contributing to tissue morphogenesis and repair. Beyond its structural role, LAMB3 expression has been implicated in regulating intracellular signaling pathways that control proliferation, migration, and apoptosis. In several cancer types, including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and others, LAMB3 is frequently upregulated and associated with enhanced invasive and metastatic potential, partly through activation of pathways such as PI3K/Akt, Wnt/β-catenin, and integrin-mediated signaling. These cancer-associated functions suggest that LAMB3 can act as a modulator of tumor progression and may represent a therapeutic or prognostic biomarker in oncology research.
Clinically, mutations in the LAMB3 gene are best known for causing junctional epidermolysis bullosa (JEB), a group of inherited blistering disorders characterized by fragility of the skin and mucosal epithelia due to defective laminin-332 and impaired adhesion between the epidermis and dermis. Severe generalized forms of JEB result from loss-of-function variants that prevent laminin-332 assembly, leading to life-threatening blistering at birth, while milder or intermediate forms manifest with chronic skin fragility and dental abnormalities. LAMB3 variants are also linked to amelogenesis imperfecta, a condition impacting enamel formation in teeth, and emerging evidence points to roles in inflammatory diseases such as Crohn's disease where LAMB3 may promote intestinal inflammation via extracellular matrix interactions. These disease associations make LAMB3 a target of interest in genetic diagnostics and therapeutics across dermatology, dentistry, gastroenterology, and oncology contexts.
Alternate Names for LAMB3
LAMB3
laminin, beta 3
LAM5
LAMNB1
BM600-125KDA
laminin subunit beta-3
nicein-125kDa
kalinin-140kDa
kalinin B1 chain
laminin B1k chain
